Correlations between Microbiological Outcomes and Clinical Responses in Patients with Severe Pneumonia
暂无分享,去创建一个
[1] R. Wunderink. Surrogate markers and microbiologic end points. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] W. Dunne,et al. Pseudomonas aeruginosa Acquires Biofilm-Like Properties within Airway Epithelial Cells , 2005, Infection and Immunity.
[3] P Stoodley,et al. Survival strategies of infectious biofilms. , 2005, Trends in microbiology.
[4] D. Andersson,et al. Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa. , 2005, The Journal of antimicrobial chemotherapy.
[5] D. Andersson,et al. Persistence of antibiotic resistant bacteria. , 2003, Current opinion in microbiology.
[6] J. Garau. Why do we need to eradicate pathogens in respiratory tract infections? , 2003, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[7] C. Stratton. Dead Bugs Don’t Mutate: Susceptibility Issues in the Emergence of Bacterial Resistance , 2003, Emerging infectious diseases.
[8] A. Tomasz,et al. From ecological reservoir to disease: the nasopharynx, day-care centres and drug-resistant clones of Streptococcus pneumoniae. , 2002, The Journal of antimicrobial chemotherapy.
[9] F. Baquero,et al. Fitness of in vitro selected Pseudomonas aeruginosa nalB and nfxB multidrug resistant mutants. , 2002, The Journal of antimicrobial chemotherapy.
[10] A. Prince. Biofilms, antimicrobial resistance, and airway infection. , 2002, The New England journal of medicine.
[11] G. Mccracken,et al. Effects of large dosages of amoxicillin/clavulanate or azithromycin on nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, nonpneumococcal alpha-hemolytic streptococci, and Staphylococcus aureus in children with acute otitis media. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] Hugues Berry,et al. Antibiotic resistance and virulence properties of Pseudomonas aeruginosa strains from mechanically ventilated patients with pneumonia in intensive care units: comparison with imipenem-resistant extra-respiratory tract isolates from uninfected patients. , 2002, Microbes and infection.
[13] C Peña,et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. , 2001, JAMA.
[14] F. Baquero,et al. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. , 2001, The Journal of antimicrobial chemotherapy.
[15] G. Mccracken,et al. Effects of amoxicillin/clavulanate or azithromycin on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] F. Ramisse,et al. Decreased virulence of a strain of Pseudomonas aeruginosa O12 overexpressing a chromosomal type 1 beta-lactamase could be due to reduced expression of cell-to-cell signaling dependent virulence factors. , 2000, FEMS immunology and medical microbiology.
[17] B. Levin,et al. The biological cost of antibiotic resistance. , 1999, Current opinion in microbiology.
[18] D. Greenberg,et al. Early eradication of pathogens from middle ear fluid during antibiotic treatment of acute otitis media is associated with improved clinical outcome. , 1998, The Pediatric infectious disease journal.
[19] Jerome J. Schentag,et al. Pharmacodynamic Evaluation of Factors Associated with the Development of Bacterial Resistance in Acutely Ill Patients during Therapy , 1998, Antimicrobial Agents and Chemotherapy.
[20] B. Balkau,et al. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. , 1998, JAMA.
[21] Jerome J. Schentag,et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group , 1994, Antimicrobial Agents and Chemotherapy.
[22] J J Schentag,et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients , 1993, Antimicrobial Agents and Chemotherapy.
[23] J. Klein,et al. Evaluation of New Anti-Infective Drugs for the Treatment of Respiratory Tract Infections , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] D. Gilbert,et al. General guidelines for the clinical evaluation of anti-infective drug products. Infectious Diseases Society of America and the Food and Drug Administration. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[25] F. Pirali,et al. Reduced virulence in ciprofloxacin-resistant variants of Pseudomonas aeruginosa strains. , 1987, The Journal of antimicrobial chemotherapy.
[26] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.
[27] J. Janda,et al. Phenotypic factors correlated with the absence of virulence among gentamicin-resistant Pseudomonas aeruginosa strains , 1984, Journal of clinical microbiology.